NordicPRO-C3™ in Tumor Fibrosis

A liquid biopsy enabling the identification of cancer patients for clinical trial enrichment and patient stratification.

How can tumor fibrosis biomarkers help clinical cancer research?

  1. The cancer field needs better actionable biomarkers to support drug development and identify patients responding to treatment.
  2. The commonly observable lack of response to treatment can be attributed to tumor fibrosis.
  3. Tumor fibrosis biomarkers should therefore be implemented in all clinical cancer trials.
  4. NordicPRO-C3™ (formerly PRO-C3) is a liquid biopsy biomarker that measures fibrotic activity in patients with solid tumors.[1]
  5. The US FDA supports the use of nordicPRO-C3™ as a non-invasive biomarker for clinical trial enrichment and patient stratification across all solid tumors.

Cancer patient stratification and enrichment strategies

Patient stratification and enrichment strategies have emerged as a crucial approaches to enhance the success rate of cancer drug development.

In this context, cancer patients exhibit varying levels of nordicPRO-C3™, which plays a significant role in determining their treatment outcomes. Patients can be categorized into two distinct groups based on their nordicPRO-C3™ levels (Figure 1.)

Higher levels of nordicPRO-C3™ in cancer patients are linked to poor survival outcomes (Figure 2.) This underscores the importance of identifying patients’ nordicPRO-C3™ levels as part of patient stratification and enrichment strategies, as it can significantly impact treatment decisions and ultimately improve the effectiveness of cancer therapies.

By tailoring treatments based on nordicPRO-C3™ levels, healthcare professionals can target the right therapies to the right patients, offering them a better chance at successful outcomes in their battle against cancer.

Watch why nordicPRO-C3™ is a milestone for tumor fibrosis studies

NordicPRO-C3™ biomarker utility in cancer (drug development perspective)

  • NordicPRO-C3™ can contribute to a better understanding of tumor fibrosis, disease progression, and response to treatment.

  • NordicPRO-C3™ can diagnose the presence of active fibrotic disease in patients with solid tumors.

  • NordicPRO-C3™ predicts the course of the disease (prognosis) and the likelihood of relapse, progression, and mortality.

  • NordicPRO-C3™ can guide treatment decisions and assist in selecting the most effective treatment options for patients.

  • NordicPRO-C3™ can be used to track the progression of a disease or the effectiveness of treatment over time

  • NordicPRO-C3™ can lead to cost savings by preventing unnecessary treatments and increasing the chance of meeting endpoints.

  • NordicPRO-C3™ is measured non-invasively in serum/plasma (liquid biopsy) and reduces the need for tissue biopsies.

  • NordicPRO-C3™ can be measured on the Roche Diagnostics cobas® e platform enabling future in-vitro diagnostic (IVD) use.[1]

Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.